title: Comparison of one-year outcomes following coronary artery stenting in diabetic versus nondiabetic patients (from the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy [ESPRIT] Trial).
abstract: For patients undergoing nonurgent coronary stent implantation, blockade of the glycoprotein IIb/IIIa receptor with eptifibatide reduces the incidence of ischemic complications. We evaluated the interaction of eptifibatide with diabetes in patients who underwent this procedure by analyzing the 1-year outcomes of those enrolled in the Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy (ESPRIT) trial (466 diabetic and 1,595 nondiabetic patients). At 1 year, the composite end point of death, myocardial infarction (MI), or target vessel revascuarlization (TVR) was higher in diabetic patients (24.5% vs 18.4%; p = 0.008). At 1 year, eptifibatide had a similar effect on the composite end point of death, MI, or TVR in diabetic (hazards ratio [HR] 0.71, 95% confidence interval [CI] 0.49 to 1.04) and nondiabetic patients (HR 0.80, 95% CI 0.63 to 0.99). A similar treatment effect was also seen on death or MI in both groups. The 1-year mortality rate for diabetic patients assigned to placebo was 3.5% versus 1.3% for patients receiving eptifibatide (HR 0.37, 95% CI 0.10 to 1.41); the latter rate was similar to the mortality rate of 1.4% for nondiabetic patients in the eptifibatide group. However, eptifibatide did not have a significant effect on TVR in diabetic patients (HR 0.90, 95% CI 0.57 to 1.41). Our data suggest that treatment with eptifibatide is associated with a similar relative reduction in adverse ischemic complications in diabetic and nondiabetic patients undergoing coronary stent implantation. There is no evidence of a statistical interaction in the treatment effect of eptifibatide between patients with and without diabetes.
authors.affiliation: University of Ottawa Heart Institute, Ottawa, Ontario, Canada. mlabinaz@ottawaheart.ca
authors.forename: Marino
authors.initials: M
authors.lastname: Labinaz
authors.forename: Mina
authors.initials: M
authors.lastname: Madan
authors.forename: J O'Conor
authors.initials: JO
authors.lastname: O'Shea
authors.forename: Rakhi
authors.initials: R
authors.lastname: Kilaru
authors.forename: Wai
authors.initials: W
authors.lastname: Chin
authors.forename: Karen
authors.initials: K
authors.lastname: Pieper
authors.forename: Darren K
authors.initials: DK
authors.lastname: McGuire
authors.forename: Jorge F
authors.initials: JF
authors.lastname: Saucedo
authors.forename: J David
authors.initials: JD
authors.lastname: Talley
authors.forename: Henry
authors.initials: H
authors.lastname: Lui
authors.forename: Michael M
authors.initials: MM
authors.lastname: Kitt
authors.forename: Robert M
authors.initials: RM
authors.lastname: Califf
authors.forename: James T
authors.initials: JT
authors.lastname: Tcheng
mesh_terms: D000284:Administration, Oral; D000368:Aged; D019917:Blood Vessel Prosthesis Implantation; D003324:Coronary Artery Disease / Q000150:complications* / Q000401:mortality / Q000628:therapy*; D048909:Diabetes Complications; D003920:Diabetes Mellitus / Q000401:mortality / Q000628:therapy*; D023381:Endpoint Determination; D000077542:Eptifibatide; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D015994:Incidence; D007328:Insulin / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000209:etiology / Q000401:mortality; D010455:Peptides / Q000627:therapeutic use*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000627:therapeutic use*; D015607:Stents; D016019:Survival Analysis; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D007004:Hypoglycemic Agents; D007328:Insulin; D010455:Peptides; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D000077542:Eptifibatide